Hepatitis C
AASLD 2015: Grazoprevir/ Elbasvir Shows High Cure Rate for People Who Inject Drugs
- Details
- Category: Experimental HCV Drugs
- Published on Sunday, 15 November 2015 00:00
Merck's grazoprevir/elbasvir coformulation demonstrated an overall sustained response rate of 92% for injection drug users receiving opioid substitution therapy in the C-EDGE CO-STAR study, according to a presentation at the 2015 AASLD Liver Meeting taking place this week in San Francisco. Participants maintained good adherence and had a high cure rate even though many continued to use illicit drugs.
IDWeek 2015: HIV/HCV Coinfected People Achieve High Cure Rates with Grazoprevir/Elbasvir
- Details
- Category: HCV Treatment
- Published on Wednesday, 11 November 2015 00:00
A dual combination of Merck's grazoprevir and elbasvir taken for 12 or 16 weeks cured most HIV-positive people coinfected with hepatitis C virus (HCV) genotypes 1, 4, or 6, and was generally safe and well-tolerated, according to an integrated analysis of three trials presented at the recent IDWeek 2015 conference in San Diego.
IHRC 2015: Community-based Drug Projects Provide an Alternative to Compulsory Detention in Asia
- Details
- Category: Injection Drug Use
- Published on Monday, 02 November 2015 00:00
A series of pilot projects in China, Indonesia, and Cambodia are showing that non-coercive, community-based drug treatment projects are feasible and more effective than the current approach of many Asian countries, incarceration and compulsory treatment, according to findings presented at the 24th International Harm Reduction Conference last month in Kuala Lumpur and in a report launched at the conference.
State Medicaid Programs Should Cover Hepatitis C Treatment, Federal Agency Says
- Details
- Category: HCV Policy & Advocacy
- Published on Tuesday, 10 November 2015 00:00
The Centers for Medicare & Medicaid Services last week issued a letter to state Medicaid programs stating that they are expected to cover new interferon-free antiviral therapies for hepatitis C without undue restrictions, as well as a letter to the pharmaceutical companies that make these drugs asking about purchasing arrangements to ensure wider access.
IHRC 2015: Why Is Injecting Equipment Reused? Drug Users Do Their Own Research to Find Out
- Details
- Category: Injection Drug Use
- Published on Monday, 02 November 2015 00:00
Even in the context of the relatively good access to harm reduction services in Australia, the principle reasons for people who inject drugs to reuse syringes relate to the convenience of services, the stigma of drug use, a fear of repercussions, and other contextual factors, according to a recent study. No participants reported sharing equipment as a choice -- if sterile equipment had been readily available at the time they needed it, they would have preferred to use it.
Gilead Requests Approval of Sofosbuvir/Velpatasvir Coformulation for All Hepatitis C Genotypes
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 02 November 2015 00:00
Gilead Sciences last week requested U.S. Food and Drug Administration (FDA) approval for a single-tablet regimen containing the hepatitis C virus (HCV) polymerase inhibitor sofosbuvir and the next-generation pangenotypic NS5A inhibitor velpatasvir, formerly known as GS-5816. Unlike the widely used sofosbuvir/ledipasvir (Harvoni), the new combination shows potent activity against HCV genotypes 1 through 6.
EACS 2015: Hepatitis C Incidence Remains Stable Among HIV-Positive Gay Men in Europe
- Details
- Category: HCV Sexual Transmission
- Published on Sunday, 01 November 2015 00:00
Researchers have seen no decline in new hepatitis C virus (HCV) infections among HIV-positive men who have sex with men in 16 European CASCADE cohorts, according to a poster presented at the 15th European AIDS Conference last week in Barcelona. However, trends seem to differ between various regions of Europe.
IHRC 2015: Hepatitis C Treatment as Prevention Must Address Concerns of People Who Inject Drugs
- Details
- Category: Injection Drug Use
- Published on Monday, 02 November 2015 00:00
While epidemiologists and public health experts are excited about the potential of new hepatitis C drugs to limit onward transmission of the virus among people who inject drugs, some strategies ignore profound barriers to drug users engaging with healthcare and their broader needs. For "treatment as prevention" to be ethical and acceptable to this people who inject drugs, enabling treatment and policy environments need to be created, according to reports at the 24th International Harm Reduction Conference last month in Kuala Lumpur.
EACS 2015: Sofosbuvir/ Ledipasvir for 8 Weeks Cures Most Hard-to-Treat Hepatitis C in Real Life
- Details
- Category: HCV Treatment
- Published on Wednesday, 28 October 2015 00:00
Most hepatitis C patients in the GECCO German hepatitis C cohort who were treated with sofosbuvir/ledipasvir (Harvoni) for 8 weeks in a real-world clinical setting achieved sustained virological response, even those who are advised to stay on treatment for 12 weeks due to factors such as liver cirrhosis, prior treatment experience, and high HCV viral load, according to a presentation last week at the 15th European AIDS Conference in Barcelona.
More Articles...
- IHRC 2015: Needle Exchanges Must Meet Needs of People Who Inject Steroids and Image-enhancing Drugs
- IHRC 2015: Harm Reduction Conference Calls for Political Leadership to Reform Drug Policy
- IHRC 2015: Peer Workers Improve Drug Users' Engagement with HIV Care in Ukraine
- FDA Warns Viekira Pak and Technivie for Hepatitis C Can Cause Serious Liver Injury
- IHRC 2015: Retreat of International Donors, National Government Neglect Threaten Harm Reduction Services
Web Design and Development by